Capecitabine for locally advanced and metastatic colorectal cancer: A review

Koukourakis, G; Zacharias, G; Tsalafoutas, J; Theodoridis, D; Kouloulias, V

dc.contributor.author	Koukourakis, G	en
dc.contributor.author	Zacharias, G	en
dc.contributor.author	Tsalafoutas, J	en
dc.contributor.author	Theodoridis, D	en
dc.contributor.author	Kouloulias, V	en
dc.date.accessioned	2014-03-01T01:59:08Z
dc.date.available	2014-03-01T01:59:08Z
dc.date.issued	2010	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28847
dc.subject	Colorectal Cancer	en
dc.subject	Cost Effectiveness	en
dc.subject	Metastatic Colorectal Cancer	en
dc.subject	neoadjuvant therapy	en
dc.subject	Overall Survival	en
dc.subject	Radiation Therapy	en
dc.subject	Rectal Cancer	en
dc.subject	Standard of Care	en
dc.subject	folinic acid	en
dc.title	Capecitabine for locally advanced and metastatic colorectal cancer: A review	en
heal.type	journalArticle	en
heal.identifier.primary	10.4251/wjgo.v2.i8.311	en
heal.identifier.secondary	http://dx.doi.org/10.4251/wjgo.v2.i8.311	en
heal.publicationDate	2010	en
heal.abstract	Capecitabine (Xeloda ® ) is an oral fluoropyrimidine which is produced as a pro-drug of fluorouracil, and shows improved tolerability and intratumor drug concentra- tions following its tumor-specific conversion to the active drug. We have searched the Pubmed and Cochrane da- tabases from 1980 to 2009 with the purpose of review- ing all available information on Capecitabine, focusing on its	en
heal.journalName	World Journal of Gastrointestinal Oncology	en
dc.identifier.doi	10.4251/wjgo.v2.i8.311	en